Charity Breast Cancer Now has described the failure to negotiate a fair price of Enhertu as “utterly heartbreaking”.

The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) says that talks with the makers ...

"Metastatic breast cancer is where breast cancer moves from the origin in the breast through the blood, and through the lymph ...

AZ and Daiichi Sankyo have said that NICE's decision on Enhertu exposes how new methods and processes the agency uses to ...

Source: Getty Images Suboptimal rates of dMMR testing and immunotherapy use suggest “a need for ongoing clinician and patient education, given the survival benefit of immunotherapy in recurrent ...

SIMULTANEOUS endometrial aspiration and sonohysterography offer a highly sensitive screening approach for detecting ...

The UK's drug pricing body has affirmed its earlier decision not to recommend coverage of AstraZeneca and Daiichi Sankyo’s ...

Breast cancer patients in England and Wales will not have access to the drug after pricing negotiations failed between NICE and drugmakers.

Nice said it was ‘extremely disappointed’ it will be unable to recommend trastuzumab deruxtecan, sold under the brand name ...

In the talks both ourselves and NHS England continued to offer as much flexibility as possible, but despite the intervention of Secretary of State for Health Wes Streeting, the companies did not put ...

The National Institute for Health and Care Excellence (Nice) said it is "extremely disappointed" it will be unable to ...